Advertisement

---

DECISION RESOURCES

In Brazil, Mexico and Argentina, High Out-of-Pocket Costs For DPP-IV Inhibitors and GLP-1 Analogues Greatly Limit Prescribing of These Drugs in the Public Setting for the Treatment of Type 2 Diabetes

[2013-07-02] - However, Patient Access to Premium-Priced Type 2 Diabetes Agents is Improving and Developers of Noninsulin Therapies Must Optimize This Opportunity, According to a New Report From Decision Resources


For Persistent Asthma, Surveyed Pulmonologists Indicate That a Reduced Rate of Exacerbations is One of the Greatest Unmet Needs

[2013-07-01] - Payers are Most Receptive to Reimbursing Premium-Priced Novel Therapies that Offer Clinical Improvements in the Rate of Severe Exacerbations, According to a New Report from Decision Resources


For Moderate To Severe Crohn's Disease, Surveyed Gastroenterologists Indicate That Higher Maintenance Of Remission Is A Top Unmet Need

[2013-06-27] - Surveyed U.S. Payers Are Particularly Receptive to New Therapies That Offer Improved Effect on Induction and Maintenance of Remission Over Currently Available Agents, According to a New Report from Decision Resources


In Metastatic Colorectal Cancer, Surveyed Managed Care Organizations Favor Avastin in Terms of Formulary Placement Over Other Targeted Agents, Correlating with High Physician-Prescribing

[2013-06-26] - A Drug's Label and Reimbursement Barriers are Factors that Impact Medical Oncologists' Sequential Prescribing of Targeted Agents, According to a New Report from Decision Resources


For Moderate to Severe Psoriasis, Thought Leaders' Opinions and Clinical Data Indicate That Emerging Biologics That Target IL-17 Have the Potential to Offer Improvements in Efficacy and Safety Over Current Therapies

[2013-06-24] - A Drug's Effect on Psoriatic Plaques at 12-16 Weeks is Highly Influential on Dermatologists' Prescribing Decisions, According to a New Report from Decision Resources


Surveyed U.S. and European Neurologists Identify Better Seizure-Free Efficacy as One of the Greatest Unmet Needs in Treating Partial-Onset Seizures in Refractory Epilepsy Patients

[2013-06-20] - Nearly All Surveyed Payers Report a Willingness to Grant Preferred Formulary Status to Drugs Delivering Such An Improvement, According to a New Report from Decision Resources


U.S. and European Rheumatologists Agree That a Therapy's Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis

[2013-06-19] - One of the Top Unmet Needs in RA is for Therapies with Greater Ability to Induce Remission Compared with Current Treatments, According to a New Report from Decision Resources


Decision Resources' Market Access Tracker Now Covers the Middle East and Africa

[2013-06-18] - Market Access Tracker Analyzes the Challenges and Opportunities of Gaining and Maintaining Favorable Market Access Terms in 24 Countries


One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to Reduce Costs

[2013-06-18] - EU5 Payers Agree that Amid Tightening Healthcare Budgets, the Growing Cost of Brands and Increasing Availability of Generics Makes HIV an Attractive Target for Cost Containment, According to a New Report from Decision Resources


Pinsonault Announces Keynote Lineup For The Fall Managed Markets Summit

[2013-06-18] -


Turkey's Non-Small-Cell Lung Cancer Drug Market Projected to Grow at 7 Percent Annually Through 2017

[2013-06-13] - Changes in Reimbursement Policy and an Increasing Incident Population Will Drive Growth Despite Price Cuts in Market, According to a New Report from Decision Resources


Rising Drug Resistance is Driving Early-Line Use of Powerful Antibiotics Such as Carbapenems for Gram-Negative Infections, According to Surveyed EU5 Physicians

[2013-06-12] - EU5 Payers Indicate that Tightening Budgets Mean Emerging Brands Must Demonstrate Compelling Cost-Effectiveness Over Current Therapies in Order to Justify Reimbursement at a Premium Price, According to a New Report from Decision Resources


Emerging Targeted Therapies Offer Efficacy Advantages Over Currently Used Chemotherapies for Platinum-Resistant Advanced Ovarian Cancer

[2013-06-10] - Overall Survival and Delayed Disease Progression is the Greatest Unmet Need in Platinum-Resistant Advanced Ovarian Cancer, According to a New Report from Decision Resources


For Second- and Subsequent-Line Metastatic Castrate-Resistant Prostate Cancer, Surveyed Oncologists Indicate that Improved Symptom Control and Quality of Life is one of the Greatest Unmet Needs

[2013-06-05] - Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Significant Median Overall Survival Benefit over Currently Available Therapies, According to a New Report from Decision Resources


Turkey's Hepatitis C Virus Drug Market Will More Than Triple by 2017

[2013-06-04] - Expansion of Therapies Offering Benefits Over Current Standard of Care Will Drive Growth Despite Price Controls in Market, According to a New Report from Decision Resources


For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies

[2013-06-03] - Efficacy Advantages of TNF-Alpha Inhibitors Will Likely Constrain Uptake of Emerging Therapies, According to a New Report from Decision Resources


Several Market Access Barriers Impede Multinational Companies From Easily Accessing Argentina's Pharmaceutical Market But Attractive Opportunities Exist

[2013-05-30] - The Commercialization Outlook for Argentina Identifies 16 Key Factors Important for Pharmaceutical Market Access, According to a New Report from Decision Resources


Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations

[2013-05-28] - Improved Safety and Tolerability Compared with Current Therapies is Another Key Market Access Lever for Emerging Neuropathic Pain Therapies, According to a New Report from Decision Resources


Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer

[2013-05-21] - Improvements in Efficacy Endpoints Including Disease Progression are Key Drivers for Prescribing in this Population, According to a New Report from Decision Resources


For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs

[2013-05-20] - Phase III Clinical Data Indicate That Indacaterol/Glycopyrronium Has Advantages Over Current Therapies for Efficacy, According to a New Report from Decision Resources


1 - 2
Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers